Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies -- Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of ...
A research team of the University Medical Center Mainz has succeeded in observing for the first time how G protein-coupled ...
Global g-protein coupled receptors (GPCRs) market growth is Driven by Rising drug discovery activities, expanding applications in targeted therapeutics, and increasing prevalence of chronic and ...
The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...
A GPS-like technique has been used to track G protein-coupled receptor movement, revealing how these essential receptors function. Although G protein-coupled receptors (GPCRs) are crucial to the ...
Just over a year after launching with $33 million in seed funding, Boston-based Superluminal Medicines is supercharging its small-molecule drug development with a $120 million series A round backed by ...
A recent study published in Engineering delves into the complex mechanisms of drug addiction, highlighting the crucial role of astrocytic G protein-coupled receptors (GPCRs). This research offers ...
Domain Therapeutics becomes Kainova Therapeutics and advances its clinical pipeline of GPCR-modulating therapies: Montreal, Canada Tuesday, January 13, 2026, 18:00 Hrs [IST] Kaino ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback